U.S. FDA extends review of Exelixis cancer drug

• The application seeks approval for zanzalintinib in combination with Roche's immunotherapy Tecentriq for treating metastatic colorectal cancer in a subset of adult patients
• The review extension was triggered by updated safety and efficacy data submitted in response to an FDA information request, classified as a major amendment
• The new FDA decision deadline is March 3, 2027, three months later than originally scheduled

Summary:

The U.S. Food and Drug Administration (FDA) has extended its review period for Exelixis' experimental colorectal cancer drug combination by three months, with a new decision deadline of March 3, 2027, according to a company filing on Friday, September 11.

The extension follows Exelixis' submission of updated safety and efficacy data in response to an FDA information request. The regulator classified this submission as a major amendment, triggering the timeline extension.

The drug under review is zanzalintinib, which Exelixis is seeking to have approved in combination with Roche's immunotherapy drug Tecentriq. The proposed treatment targets a subset of adult patients with metastatic colorectal cancer.

Market Implications:

This review extension represents a regulatory setback for Exelixis, delaying potential market entry by a quarter. The three-month postponement could impact the company's revenue projections and competitive positioning in the colorectal cancer treatment market. For Roche, as the partner providing Tecentriq for the combination therapy, the delay may also affect strategic planning around this indication.

Review extensions classified as "major amendments" typically indicate the FDA requires substantial additional information before making an approval decision, which may signal regulatory concerns or the need for more comprehensive data analysis. Investors should monitor whether this delay suggests potential approval challenges or is simply procedural.

The colorectal cancer treatment market represents a significant commercial opportunity, making this approval decision financially material for both Exelixis and Roche. The extended timeline provides competitors additional time to advance their own therapies in this indication.